Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001580642-25-005132
Filing Date
2025-08-14
Accepted
2025-08-14 14:59:36
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9891
  Complete submission text file 0001580642-25-005132.txt   11933
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-37761 | Film No.: 251217829
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address ONE INTERNATIONAL PLACE SUITE 4210 BOSTON MA 02110
Business Address ONE INTERNATIONAL PLACE SUITE 4210 BOSTON MA 02110 877-771-3836
EVENTIDE ASSET MANAGEMENT, LLC (Filed by) CIK: 0001442891 (see all company filings)

EIN.: 262508416 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A